Related references
Note: Only part of the references are listed.Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers
Lele Xu et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study
Clifford R. Jack et al.
LANCET NEUROLOGY (2016)
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease
Akanksha Kulshreshtha et al.
NEUROLOGICAL SCIENCES (2016)
Meta-analytic Comparison Between PIB-PET and FDG-PET Results in Alzheimer's Disease and MCI
Wei He et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
Kevin T. Ong et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment
Nina Kemppainen et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy
Tapan K. Khan et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Daniel M. Michaelson
ALZHEIMERS & DEMENTIA (2014)
Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia
Paula T. Trzepacz et al.
NEUROBIOLOGY OF AGING (2014)
Early detection of Alzheimer's disease using PiB and FDG PET
Ann D. Cohen et al.
NEUROBIOLOGY OF DISEASE (2014)
Predictive Accuracy of Amyloid Imaging for Progression From Mild Cognitive Impairment to Alzheimer Disease With Different Lengths of Follow-up A Systematic Review
Yan Ma et al.
MEDICINE (2014)
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Stephen Salloway et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Predicting Alzheimer Disease with β-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Christopher C. Rowe et al.
ANNALS OF NEUROLOGY (2013)
[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment
A. Bruck et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Imaging markers for Alzheimer disease Which vs how
Giovanni B. Frisoni et al.
NEUROLOGY (2013)
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease
D. P. Devanand et al.
NEUROIMAGE (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
An Open Source Multivariate Framework for n-Tissue Segmentation with Evaluation on Public Data
Brian B. Avants et al.
NEUROINFORMATICS (2011)
Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment
D. P. Devanand et al.
NEUROLOGY (2011)
Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease
Y. Chen et al.
NEUROLOGY (2011)
Pittsburgh Compound B (11C-PIB) and Fluorodeoxyglucose (18F-FDG) PET in Patients With Alzheimer Disease, Mild Cognitive Impairment, and Healthy Controls
D. P. Devanand et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2010)
In Vivo Quantification of Human Serotonin 1A Receptor Using 11C-CUMI-101, an Agonist PET Radiotracer
Matthew S. Milak et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Relative Capability of MR Imaging and FDG PET to Depict Changes Associated with Prodromal and Early Alzheimer Disease
David S. Karow et al.
RADIOLOGY (2010)
Fluorodeoxyglucose-Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis
Y. Yuan et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2009)
Modeling considerations for in vivo quantification of the dopamine transporter using [11C]PE2I and positron emission tomography
Christine DeLorenzo et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2009)
Conversion of amyloid positive and negative MCI to AD over 3 years An 11C-PIB PET study
A. Okello et al.
NEUROLOGY (2009)
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment
N. M. Kemppainen et al.
NEUROLOGY (2007)
Hippocampal and entorhinal atrophy in mild cognitive impairment - Prediction of Alzheimer disease
D. P. Devanand et al.
NEUROLOGY (2007)
Consensus nomenclature for in vivo imaging of reversibly binding radioligands
Robert B. Innis et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2007)
Estimation in regression models with externally estimated parameters
RT Ogden et al.
BIOSTATISTICS (2006)
Amyloid plaque imaging agent [C-11]-6-OH-BTA-1:: biodistribution and radiation dosimetry in baboon
Ramin V. Parsey et al.
NUCLEAR MEDICINE COMMUNICATIONS (2005)
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease - FDG-PET studies in MCI and AD
L Mosconi
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Overall C as a measure of discrimination in survival analysis:: model specific population value and confidence interval estimation
MJ Pencina et al.
STATISTICS IN MEDICINE (2004)
Share Paper
